Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabien Vincent

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Biochemical and Biophysical Research Communications|September 10, 2009
Identification and characterization of novel TRPV4 modulatorsFabien Vincent, Alejandra Acevedo, Margaret T Nguyen, et al.
Molecular Biology of the Cell|March 11, 2011
Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal deathKuei-Hua Chang, Parminder Singh Multani, Kai-Hui Sun, et al.
ACS Medicinal Chemistry Letters|November 20, 2024
Cyclic Peptide C5aR1 Antagonist Design Using Solution Conformational Analysis Derived from Residual Dipolar CouplingsKathleen A Farley, Ye Che, Ricardo Lira, et al.
Protein Science : a Publication of the Protein Society|September 24, 2017
The catalytic mechanism of cyclic GMP-AMP synthase (cGAS) and implications for innate immunity and inhibitionJustin Hall, Erik C Ralph, Suman Shanker, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2015
Identification of orally-bioavailable antagonists of the TRPV4 ion-channelZhi-Liang Wei, Margaret T Nguyen, Donogh J R O'Mahony, et al.
European Journal of Medicinal Chemistry|January 20, 2018
Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitorsFrank Lovering, Paul Morgan, Christophe Allais, et al.
ACS Chemical Biology|September 24, 2024
Discovery, Characterization, and Structure of a Cell Active PAD2 Inhibitor Acting through a Novel Allosteric MechanismLaura J Byrnes, Won Young Choi, Paul Balbo, et al.
Cell Reports|June 9, 2021
Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validationXuan Huang, Kasper C D Roet, Liying Zhang, et al.
Bioorganic & Medicinal Chemistry|April 8, 2020
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Journal of Medicinal Chemistry|February 1, 2017
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Biochemical and Biophysical Research Communications|September 10, 2009
Identification and characterization of novel TRPV4 modulatorsFabien Vincent, Alejandra Acevedo, Margaret T Nguyen, et al.
Molecular Biology of the Cell|March 11, 2011
Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal deathKuei-Hua Chang, Parminder Singh Multani, Kai-Hui Sun, et al.
ACS Medicinal Chemistry Letters|November 20, 2024
Cyclic Peptide C5aR1 Antagonist Design Using Solution Conformational Analysis Derived from Residual Dipolar CouplingsKathleen A Farley, Ye Che, Ricardo Lira, et al.
Protein Science : a Publication of the Protein Society|September 24, 2017
The catalytic mechanism of cyclic GMP-AMP synthase (cGAS) and implications for innate immunity and inhibitionJustin Hall, Erik C Ralph, Suman Shanker, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2015
Identification of orally-bioavailable antagonists of the TRPV4 ion-channelZhi-Liang Wei, Margaret T Nguyen, Donogh J R O'Mahony, et al.
European Journal of Medicinal Chemistry|January 20, 2018
Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitorsFrank Lovering, Paul Morgan, Christophe Allais, et al.
ACS Chemical Biology|September 24, 2024
Discovery, Characterization, and Structure of a Cell Active PAD2 Inhibitor Acting through a Novel Allosteric MechanismLaura J Byrnes, Won Young Choi, Paul Balbo, et al.
Cell Reports|June 9, 2021
Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validationXuan Huang, Kasper C D Roet, Liying Zhang, et al.
Bioorganic & Medicinal Chemistry|April 8, 2020
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Journal of Medicinal Chemistry|February 1, 2017
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.
Pageof 5